Rates of Invasive Pneumococcal Disease in Adults With HIV in the Era of 13-Valent Pneumococcal Conjugate Vaccine, 2008-2018

Source: IDWeek 2021: Clinical Impact of New Data*
Download Slideset
September 29 - October 3, 2021; Virtual
Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.
Format: Microsoft PowerPoint (.ppt)
File Size: 419 KB
Released: October 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Prof. Don Smith addresses what healthcare professionals in Australia need to know about long-acting antiretroviral agents, from Clinical Care Options (CCO)

Prof. Don Smith Released: November 23, 2021

Dr Roger Bedimo discusses the need for prophylaxis for Pneumocystis jirovecii pneumonia in virologically suppressed patients, from Clinical Care Options (CCO)

Roger Bedimo, MD, MS, FACP Released: November 23, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue